Sito in Italia dove è possibile acquistare la consegna acquisto Viagra a buon mercato e di alta qualità in ogni parte del mondo.

Program_for_print.indd

PROGRAMME
WEDNESDAY 20 NOVEMBER 2013
WEDNESDAY 20 NOVEMBER 2013
8.00-9.00
Clinical Leaders Meeting-SHED 6, ROOM 1
8.30-9.45
Delegate Arrival and Registration
Welcome | President NZSG and NZGNS: A/Prof Alan Fraser and Cathryn Whiteside
9.45-10.00
Convenors: Dr Jeffrey Wong and Cathryn Whiteside
SESSION 1 | General Plenary Session (Joint session)
Chair: A/Prof Alan Fraser and Dr Stephen Inns SHED 6, ROOM 1
10.00-10.30
Achieving quality endoscopy in the UK I Prof Matt Rutter
10.30-11.00
Crohn’s Disease and its Evolution: From Observations to Individualized Therapy I Dr David Rubin
11.00-11.20
Iron and the Liver I Dr Kris Kowdley
11.20-11.40
Quality colonoscopy: To and from the Caecum I Prof Michael Bourke
11.40-12.00
Advancing IBD Nursing in Europe I Marian O’Connor
12.00-1.00
Lunch and Exhibition
SESSION 2 | Endoscopy Quality Improvement Programme
Chair: Dr Tim King SHED 6, ROOM 1
1.00-1.35
The National Endoscopy Quality Improvement Programme I Mr David Theobald and Jenni Masters
SESSION 3 | I BD
SESSION 3A | Upper G I
SESSION 3B | Nurses professional session
Chair: Dr Stephen Inns SHED 6, ROOM 1
Chair: Dr David Rowbotham SHED 6, ROOM 2
Chair: Katherine Broome SHED 6, ROOM 4
Microbiota and faecal transplant
Capsule Endoscopy: The next 5 years
Endoscope Disinfection: Where are
1.40-2.10
1.40-2.10
1.40-2.10
we now? I Di Jones
Host-microbe interactions have
shaped the genetic architecture of

Bravo: Wireless pH monitoring
Knowledge and skills framework
2.10-2.25
2.10-2.25
2.10-2.25
infl ammatory bowel disease
Iron defi ciency in infl ammatory bowel
Genetic Counselling and Gastro
2.25-2.40
2.25-2.40
Impedance I Dr Ian Wilson
2.25-2.40
disease I Dr Melissa Haines
Nurses I Michelle Lau
The role of the infl ammatory bowel
Emerging treatment options for Refl ux
2.40-3.00
2.40-3.00
2.40-3.00
Prison based HCV Clinics I Ying Eu
disease nurse I Marian O’Connor
3.00-3.30
Afternoon Tea
SESSION 4A | Paediatric Gastroenterology:
SESSION 4 | Hepatitis C
SESSION 4B | Nurses professional session cont’d
What Adult Gastroenterologists Need to Know
Chair: Prof Ed Gane SHED 6, ROOM 1
Cha ir: Ying Eu SHED 6, ROOM 4
Chair: Dr Helen Evans SHED 6, ROOM 2
Hepatitis C Treatments: The Next 5
Setting up a Colo-rectal Surgery
3.30-4.00
3.30-3.50
Coeliac Disease I A/Prof Don Cameron
3.30-3.50
Years I Dr Kris Kowdley
Nurse led clinic I Jenny Keene
Who to treat now and who to wait
Stomaltherapy - Getting to the Guts
4.00-4.15
3.50-4.10
Paediatric IBD I Prof Andrew Day
3.50-4.10
of the Matter I Vicky Beban
The Pilot HCV Community Assessment
Transition: What happens when your
Peri-procedural Diabetes Care
4.15-4.30
and Support Programme
4.10-4.30
patients become our patients?
4.10-4.30
The HCV Pilot: Benefi ts for Clinicians Dr
4.30-4.45
4.30-4.40
Questions
4.30-4.40
Questions
4.45-5.00
Questions
5.00-6.00
Welcome Function
7.00-Late
Doctors Dinner and Nurses Dinner
PROGRAMME
THURSDAY 21 NOVEMBER 2013
THURSDAY 21 NOVEMBER 2013
7.00-8.00
The 2nd Annual Great Guts Fun Run (proudly sponsored by AbbVie)
SESSION 5 | Luminal – Free Papers
SESSION 5B | Nurses Free Papers
SESSION 5A | Hepatology – Free Papers
1st Time Presenters
Chair: Dr Jeffrey Wong SHED 6, ROOM 2
SHED 6, ROOM 1
Chair: Jenni Masters SHED 6, ROOM 4
Use of Fibroscan in the assessment
A Silent Illness – Primary Biliary
Osteoprotegerin: a pro-infl ammatory
8.30-8.45
8.30-8.45
of chronic hepatitis B infection
8.30-8.45
Cirrhosis: One Patient’s perspective
role in IBD I Andrew Day
Retrospective comparison of
The Descriptive Epidemiology
Radiofrequency and Microwave
8.45-9.00
of Infl ammatory Bowel Disease in
8.45-9.00
8.45-9.00
Bizarre Bezoars I Katrina Wheatley
ablation for Hepatocellular Carcinoma
Nelson, New Zealand I Darryl Fry
A reduction in FODMAP intake
Tenofovir use in chronic hepatitis B
Reducing polypectomy readmission
correlates strongly with a reduction in
9.00-9.15
9.00-9.15
infection women during pregnancy:
9.00-9.15
rates in Bowel Screening Pilot
IBS symptoms-The FIBS study
Auckland Experience I Judy Huang
Programme I Thelma Turner
Malnutrition Screening in Hospitalised
15 Years of Liver Transplant
Colonoscopy: Supply and Demand
Patients; Laboratory test (Prealbumin)
Assessments for Chronic Liver
9.15-9.30
9.15-9.30
9.15-9.30
at Counties Manukau District Health
versus Routine Clinical Assessment
Disease: A Single Centre Experience
Board I Naomi Reed
The prevalence of abnormal liver
mir-1247 is Down-Regulated in
enzymes in New Zealand: fi ndings
Medication Safety in
9.30-9.45
CpG island Methylator Phenotype
9.30-9.45
9.30-9.45
from the 2008/09 Adult Nutrition
Gastroenterology I Yasmin Reddy
Colorectal Cancers I Jennifer Liang
Survey I Kirsten Coppell
What do endoscopy nurses believe is
Biliary dilatation induced by different
T cell distribution in gastrointestinal
necessary for a Nurse Endoscopist
9.45-10.00
9.45-10.00
opiate drugs – a case series
9.45-10.00
infl ammatory disorders I Elliott Dunn
role to develop in New Zealand?
10.00-10.30
Morning Tea and Exhibition
SESSION 6 | Presidential Young Investigators Free Papers
SESSION 6A | Nurses Free Papers Con’td
Chair: A/Prof Alan Fraser SHED 6, ROOM 1
Chair: Janice Duxfield SHED 6, ROOM 4
Preserved colonic meal response and functional evidence for
Why so slow? Rapid Iron Polymaltose infusions are well tolerated
10.30-10.45
anastomotic nerve regeneration in patients with normal bowel
10.30-10.45
in an outpatient setting I Urmilla Kumar
function following anterior resection I Ryash Vather
Bitter taste receptors within the gastrointestinal tract
Psychological factors and personality traits in Infl ammatory Bowel
10.45-11.00
10.45-11.00
Disease: How to understand our IBD Patients better? I Irit Bialik
Spontaneous maturation of organoids grown from isolated human
Optimise or switch?–What to do when IBD patients fail anti-TNF-
11.00-11.15
11.00-11.15
colonic biopsies I Ely Rodrigues
drugs I Kirsten Rosser
Patient preferences for care in end stage liver disease
Christchurch Hospital Infl ammatory Bowel Disease (IBD) Audit
11.15-11.30
11.15-11.30
Nursing Outcomes I Holly Weale
11.40-12.00
Trans-Tasman Lecture–50 Years of Australian and New Zealand Paediatric Gastroenterology I A/Prof Don Cameron
12.00-13.00
Lunch and Exhibition & Formal Poster Round–Poster Judging
SESSION 7 | Colon Cancer in IBD
SESSION 7A | Nurses AGM
SESSION 7B | RACP – Adult Medicine
Chair: A/Prof Richard Gearry SHED 6, ROOM 1
Chair: Cathryn Whiteside SHED 6, ROOM 4
Young Investigators Awards SHED 6, ROOM 2
Update in Colorectal Cancer in
Colitis: Towards an Individualized

Prevalence of autoantibodies in
1.00-1.20
Approach
idiopathic infl ammatory myopathy and/
or interstitial pneumonia
Dr Rama Kalluru
Surveillance in IBD: The State of the
1.20-1.40
Art I Prof Matt Rutter
Inhibition of 5-reductase type 1 with
dutasteride in men increases body fat

Reducing Colon Cancer Risk with
1.00-2.30
1.00-2.30
and impairs insulin sensitivity
1.40-2.00
Drugs I A/Prof Michael Schultz
Surgery for Cancer in IBD
Diagnosis of myocardial infarction after
2.00-2.20
coronary artery bypass grafting with
high-sensitivity troponin: validation of
the universal defi nition

2.20-2.30
Discussion
2.30-3.00
Afternoon Tea and Exhibition
PROGRAMME
THURSDAY 21 - FRIDAY 22 NOVEMBER 2013
SESSION 8 | Colonoscopy
SESSION 8A | Liver Cancer
SESSION 8B | Nurse Professional Session
Chair: Dr Michael Burt SHED 6, ROOM 1
Chair: Dr Richard Stein SHED 6, ROOM 2
Chair: Kirsten Rosser SHED 6, ROOM 4
Advanced Polypectomy in the Colon
Hepatocellular Carcinoma in New
IBD for Endoscopy Nurses
3.00-3.30
3.00-3.20
3.00-3.30
Zealand I Prof Ed Gane
What are the important KPI’s
Diagnosis and staging of HCC in 2013
Nurses Role in Endoscopy Quality
3.30-3.50
3.20-3.40
3.30-3.45
Improvement I Jenni Masters
Colonic Tatooing
Standards for Endoscopic Facilities
3.50-4.00
3.40-4.00
Surgery for HCC I Mr Adam Bartlett
3.45-4.00
and Services I Di Jones
SESSION 9 | Oral poster presentations (5x5min slots-3 slide poster
SESSION 9A | Advanced ER in the UGIT
presentations) Chair: Dr Stephen Inns SHED 6, ROOM 1
Chair: Dr Rees Cameron SHED 6, ROOM 2
Faecal S100A12 in healthy infants and children I Andrew Day
Colorectal Cancer After Colonoscopy: Risk Factors And
Survival Data Compared With Cancer Diagnosed At Time Of
Colonoscopy
I Nathan Atkinson
Infl ammatory bowel disease patient preferences for a
computerised over face-to-face psychological intervention

4.05-4.30
4.05-4.30
Video Cases I Prof Michael Bourke
CAPER score as a prioritization tool for colonoscopy grading in
colorectal cancer investigation in Bay of Plenty DHB
Judy Huang
Infl ammatory Bowel Disease Mortality in Canterbury, New
Zealand
I A Forbes
4.30-6.00
NZSG AGM I SHED 6, ROOM 2
7.00-Late
Conference Dinner I The Renouf Foyer, Michael Fowler Centre, Wellington I Bilbo goes to the Sevens
FRI DAY 22 NOVEMBER 2013
SESSION 10 | General Hepatology
SESSION 10A | Nurses Hands on Session
Chair: Dr Stephen Gerred SHED 6, ROOM 1
Chair: Katherine Broome SHED 6, ROOM 4
9.00-9.30
Non Alcholic fatty liver Disease I Dr Kris Kowdley
9.30-10.00
An Update on Hepatitis B In New Zealand I Prof Ed Gane
Gastroenterologists role in the care of the patient with a Liver
10.00-10.30
transplant I Dr Dominic Ray-Chaudhuri
10.30-11.00
Morning Tea and Exhibition
SESSION 11 | General Session (Joint Session)
Chair: Dr Richard Stein SHED 6, ROOM 1
11.00-11.20
Colonoscopy Services Across New Zealand I A/Prof Susan Parry
11.20-11.40
Nurse Endoscopy in Australia I Di Jones
11.40-12.00
Population Colon Cancer Screening: How to achieve equity I A/Prof Diana Sarfati
12.00-12.15
Closing Remarks
12.15-1.15
NB: Prelim Programme is subject to change without notice

Source: http://www.gastro2013.co.nz/downloads/Programme_Nov13.pdf

nippc.org

UNITED STATES OF AMERICA BEFORE THE FEDERAL ENERGY REGULATORY COMMISSION MOTION TO ANSWER AND ANSWER OF EXELON TO THE IDAHO PUBLIC UTILITIES COMMISSION Pursuant to Commission Rules 212 and 213,1 Exelon Corporation (“Exelon”) submits this limited Answer to the Answer filed by the Idaho Public Utilities Commission (“Idaho PUC”) in this proceeding. Exelon submits that Ce

Microsoft word - anaesthesia - released jan 2006.doc

T H E U N I V E R S I T Y O F M E L B O U R N E A N I M A L W E L F A R E C O M M I T T E E G U I D E L I N E S F O R G E N E R A L A N A E S T H E S I A A N D A N A L G E S I A O F C O M M O N L A B O R A T O R Y A N I M A L S I n t r o d u c t i o n Anaesthesia means without ('an') feeling ('aesthesia') and general anaesthetic agents are drugs which typically produce a progr

Copyright © 2010-2014 Medicament Inoculation Pdf